No Trial Has Shown Magnesium Glycinate Keeps People Awake

No clinical trial and no published case report has found that magnesium glycinate causes insomnia or paradoxical wakefulness. At Longevity Benchmark, we evaluate supplement claims by separating verified trial outcomes from plausible receptor biology. The sleep evidence for oral magnesium itself remains modest, and controlled trials of magnesium bisglycinate record no reports of nocturnal activation or nighttime alertness.

The Evidence on Magnesium Glycinate and Wakefulness

No clinical trial or published case report demonstrates that magnesium glycinate causes insomnia, paradoxical wakefulness, or nocturnal agitation. Only one randomised trial has tested magnesium bisglycinate for sleep, and its magnesium arm recorded two adverse events across 77 participants, none of them gastrointestinal and none involving sleep. That trial, published by Schuster and colleagues in 2025, evaluated 155 adults over four weeks. The sole report of sleep disturbance came from the placebo arm. The placebo group also recorded the only instances of headaches, dizziness, nausea, frequent urination, increased nighttime thirst, and joint pain. Overall, 93% of participants reported no adverse events.

The broader meta-analysis literature shows a matching absence of wakefulness signals. In a 2021 systematic review of oral magnesium for insomnia in older adults by Mah and Pitre, the only reported unintended effect was loose stools. No patient reported excitation or nocturnal alertness. A biological mechanism for wakefulness is theoretically possible because glycine interacts with excitatory receptors in the brain. However, a theoretical mechanism is not a demonstrated clinical effect.

Clinical Trial Outcomes for Magnesium and Sleep

Clinical trial evidence showing that oral magnesium improves sleep quality remains modest, inconsistent, and limited by study quality. Mah and Pitre pooled three trials in 151 older adults in 2021. Sleep onset latency fell by 17.36 minutes against placebo (95% CI -27.27 to -7.44, p = 0.0006). Total sleep time improved by 16.06 minutes, but that change was not statistically significant. Doses in those trials ranged from 320 mg to 729 mg of elemental magnesium daily from oxide and citrate forms. None evaluated magnesium glycinate.

The authors graded their evidence base as low to very low quality. All three trials showed moderate-to-high risk of bias. A December 2024 correction to that paper altered only an abbreviation, a database name and the search-flow record counts, and revised no effect estimate and no conclusion. In the 2025 Schuster trial the Insomnia Severity Index fell 3.9 points on magnesium and 2.3 on placebo. The between-group p was 0.049 and Cohen's d was 0.2, which the authors call a modest benefit. Fewer than 10% of participants completed daily sleep logs. That trial gave 250 mg of elemental magnesium and 1,523 mg of glycine in the same capsule, with no magnesium-only and no glycine-only comparator, so it cannot say which of the two produced the change.

Other systematic reviews confirm this mixed picture. In a 2025 review of 28 trials by Mei and colleagues, magnesium was not among the isolated effective sleep supplements. An analysis of 21,840 NHANES participants by Zhao and colleagues found dietary magnesium linked to sleep duration (OR 1.07, 95% CI 1.01 to 1.14, p = 0.024). It showed no link to sleep disorders (OR 0.96, 95% CI 0.90 to 1.03, p = 0.238). Magnesium supplementation was not associated with either duration or disorders.

The Glycine Load in a Labelled Magnesium Dose

Magnesium bisglycinate is composed primarily of glycine by molecular weight, delivering roughly six times more amino acid mass than elemental mineral. Chemical records in PubChem identify magnesium bisglycinate (CID 84645) as a compound with a molecular weight of 172.42 g/mol. Glycine (CID 750) has a molecular weight of 75.07 g/mol, and elemental magnesium has an atomic weight of 24.305. Elemental magnesium represents 14.1% of anhydrous magnesium bisglycinate by mass. The remaining 85.9% consists of two glycinate ligands.

Delivering 100 mg of elemental magnesium requires roughly 709 mg of raw chelate. That amount carries about 609 mg of glycine. The capsules used in the 2025 trial came to 1,786 mg of bisglycinate for that 250 mg, because the trial product assayed at 14.0% rather than the anhydrous 14.1%. Reaching the 3 g glycine dose of the published glycine trials would take about 490 mg of elemental magnesium in one evening serving. That is above the supplemental upper limit discussed in the safety section below.

Why Glycine Could Cut Either Way at the Receptor Level

Glycine acts as both an inhibitory neurotransmitter and an excitatory co-agonist in the central nervous system, creating two biologically opposing pathways. In human trial literature, Bannai and colleagues note that glycine acts as an inhibitory neurotransmitter via glycine receptors. It also acts as an excitatory co-agonist at NMDA glutamate receptors. Binding at this co-agonist site is required for the NMDA channel to open, as reviewed by Schmidt and Thompson. The site is not saturated at rest.

Rodent work points the other way: glycine's sleep-promoting action appears to run through NMDA receptors, not through the inhibitory glycine receptor. In animal experiments by Kawai and colleagues, oral glycine reduced core temperature by increasing cutaneous blood flow. The NMDA receptor antagonists AP5 and CGP78608 significantly attenuated that effect. Meanwhile, the glycine receptor antagonist strychnine did not inhibit the glycine-induced rise in cutaneous blood flow. That puts NMDA receptors in the suprachiasmatic nucleus at the centre of the response. Magnesium sits on the opposite side of the channel. As Wollmuth and colleagues showed, extracellular magnesium produces a voltage-dependent block at physiological concentrations near 1 millimolar.

Published human sleep trials test 3 g of glycine taken 30 minutes before bed. Bannai and colleagues tested this dose in seven sleep-restricted volunteers. Glycine reduced daytime fatigue and improved reaction time. Earlier work by Yamadera and colleagues observed shortened sleep latency on polysomnography following 3 g of glycine. Doses that alter NMDA outcomes in clinical psychiatry range from 15 to 60 g daily. At those levels, nausea and taste intolerance limit use, not insomnia or agitation.

The Bedtime Variables with Better Evidence Behind Them

Common evening habits such as late caffeine intake and alcohol consumption impair sleep through mechanisms that have strong clinical trial support. In a trial by Drake and colleagues, 400 mg of caffeine taken six hours before bed reduced total sleep time by more than an hour. Participants did not perceive this sleep loss subjectively. Objective monitors still recorded the deficit.

Alcohol also disrupts nocturnal sleep architecture. In a 2025 meta-analysis by Gardiner and colleagues, alcohol delayed REM sleep onset and shortened REM duration. This disruption began at two standard drinks (0.50 g/kg) and worsened with higher intake. Reductions in sleep onset latency appeared only at heavy intakes around five standard drinks (0.85 g/kg). Effects on total sleep time and wakefulness after sleep onset showed wide uncertainty.

Vitamin D timing remains unstudied in clinical trials. A 2022 review by Abboud showed improved sleep scores across 19 studies, but none evaluated administration time. One included study noted sleep quality deterioration upon vitamin D repletion. Adverse events are common in placebo arms too. In an overview of 1,271 randomised trials and 250,726 placebo-treated patients by Howick and colleagues, the median adverse-event prevalence across placebo groups was 49.1%. The authors conclude those events cannot be put down entirely to natural history.

Label Discrepancies and Oxide Declarations in Commercial Bottles

Roughly three in ten magnesium glycinate products currently on the US market declare magnesium oxide on the same label. This figure comes from counts of what labels state rather than any chemical assay of capsule contents. The Food and Drug Administration does not approve dietary supplements before they reach retail shelves. Under 21 CFR 101.9(g)(4), added minerals must equal at least 100% of the declared amount. Naturally occurring minerals must reach at least 80%.

Federal warning letters show that label amounts are not always present. An FDA warning letter to Hello Life, Inc. documented a supplement containing 77.5 mg of magnesium per serving, or 62% of the declared quantity. Another FDA warning letter to Evimeria El Aztecano, Inc. cited mineral levels below 80% of declared values. The Federal Trade Commission secured a $2.1 million settlement with NBTY and NatureSmart in 2010 after multivitamins touting 100 mg of DHA were found to contain 0.1 mg. That was one thousandth of the advertised amount.

Blending forms is common in commercial products. In NIH Dietary Supplement Label Database records, 1,471 products named magnesium glycinate or bisglycinate. Of those, 555 products (37.7%) also listed magnesium oxide. Among 528 on-market records, 162 (30.7%) declared magnesium oxide, some using names like Magnesium Glycinate Buffered. What a buffered blend changes about tolerability and elemental content is covered in our magnesium form comparison.

Systematic Elimination of the Evening Supplement

A single-variable pause is the most reliable way to determine whether an evening magnesium capsule causes sleep disruption. Stop taking the supplement for several nights while holding your sleep environment, afternoon habits, and wake time steady. Track whether sleep onset latency or nighttime awakenings change while the capsule is absent. Check the product label for other active ingredients.

Many commercial sleep supplements combine magnesium with vitamin B6. In an eight-week trial by Pouteau and colleagues, 268 adults received 300 mg of elemental magnesium with or without 30 mg of vitamin B6. Adverse events occurred in 41% of the combination arm and 40% of the magnesium-alone arm, consisting almost entirely of diarrhea and mild digestive complaints. No sleep disturbances or neurological side effects were reported.

If the alertness goes while the supplement is out, the supplement is the primary suspect. The next question is which part of it is responsible: the magnesium, the glycine, or something else on the label. None of the obvious adjustments has been tested in a trial. Treat any change as a personal experiment rather than an established fix, and resolve dose questions with your clinician. No trial has tested whether moving magnesium glycinate to the morning changes an evening response, so treat that as something to try rather than something known to work.

Safety boundaries remain defined by kidney capacity and published intake guidelines. The Institute of Medicine established a tolerable upper intake level of 350 mg daily for supplemental magnesium in adults, as reviewed by Costello and colleagues. That 1997 figure rests on a single endpoint, diarrhoea. The 2023 perspective that reviews it reports that seven of ten newer studies at 128 to 1,200 mg per day found no significant difference in diarrhoea against control. Treat 350 mg as the standing official limit, not as a settled toxicity threshold. Healthy kidneys excrete excess magnesium efficiently. In renal failure, however, over-the-counter magnesium can cause life-threatening hypermagnesemia. As Khairi and colleagues reported, a patient with impaired kidneys developed plasma magnesium of 11 mg/dL, suffering loss of deep tendon reflexes, hypotension, and respiratory compromise. Normal plasma magnesium sits between 1.7 and 2.4 mg/dL. Anyone with kidney disease must not self-dose magnesium supplements. Consult our magnesium side effects review for full guidance on limits and digestive tolerance.

Clinical Assessment Options for Persistent Sleep Issues

Sleep problems that persist after stopping evening magnesium point toward primary sleep pathology rather than a supplement reaction. Nutritional supplements cannot resolve chronic insomnia, sleep apnea, or circadian rhythm misalignments. If difficulty initiating or maintaining sleep continues, clinical evaluation is the appropriate next step. Tracking sleep stages can help contextualize your symptoms. Our guide on sleep scores explains how wearable devices assess nightly rest. You can also review our guide to how much deep sleep you need to understand restorative sleep stages.

Breathing disruptions frequently cause unexplained nocturnal awakenings. If you experience snoring, morning headaches, or unrefreshing sleep, consider a formal diagnostic evaluation. Our home sleep apnea test comparison details testing equipment and clinical workflows. If evening magnesium is what changed, pausing it for a few nights is the cheapest way to find out. If the wakefulness persists without it, the magnesium was not the variable and a clinician is the next step. For everyone else, glycinate in the evening remains the sensible default, and our magnesium form comparison covers the general case.

What would change our answer is new trial data. Our assessment would change if controlled trials show that magnesium bisglycinate provokes nocturnal wakefulness, or if clinical studies demonstrate that shifting dosage timing reliably alters sleep latency. To address your sleep tonight, check your supplement label for declared oxide or added vitamins. Stop caffeine at least six hours before bedtime, and consult your physician if the wakefulness continues once magnesium is out of the routine.

Related

• Best Magnesium Supplements: Forms, Doses, and Timing
• Magnesium Supplement Side Effects and Safety Evidence
• Deep Sleep Requirements and Architecture Benchmarks
• Sleep Score Metrics and Wearable Data Interpretation
• Home Sleep Apnea Testing and Clinical Assessment
• Deep Sleep Supplement Evidence and Limits